Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
CagriSema Shows Strong Dual-Hormone Promise in Obesity and T2D: Key Findings from REDEFINE Trials CagriSema, a once-weekly combination of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide, offers a dual mechanism targeting both appetite suppression and glycemic regulation
Science doesnt yet know whether it really does help women reduce painand the influencers or certified peptide coaches who promote them dont know either
This multi-receptor activation enables: GLP-1R activation enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic signaling GIPR activation (highest potency: EC50 0.0643 nM) promotes insulin secretion and modulates lipid metabolism GCGR activation (EC50 5.79 nM) increases energy expenditure and promotes hepatic fat oxidation Combined receptor engagement produces dose-dependent reductions in body weight and improvements in glycemic control Research demonstrates that GLP3s balanced activation across three receptors produces superior metabolic effects compared to single or dual agonists, with phase 2 trials showing up to 24.2% weight reduction in 48 weeks[2]
The right protocol, the right product, and the right team make all the difference
